FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use
Gilead is one step closer to unlocking a potentially blockbuster new use of its two-drug HIV regimen Descovy — though probably not all of it.
In a meeting late Wednesday, the FDA’s Antimicrobial Drugs Advisory Committee voted 16 to 2 endorsing Descovy as a pre-exposure prophylaxis, or PrEP, in men and transgender women who have sex with men. On the question of expanding the indication to include cisgender women, though, a slight majority of experts (10 versus 8) voted against it, citing a lack of data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.